热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse TCR β
产品名称：
Brilliant Violet 421™ anti-mouse TCR β
产品类别：
抗体
产品编号：
109229
产品应用：
109229
[价格]
规格 价格 库存
125µL ￥ 2112 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Affinity purified TCR from mouse DO-11.10 cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

H57-597 is a hamster mAb directed to an epitope of the C region of TCR ? chain12. The H57-597 antibody does not cross-react with ?/d TCR-bearing T cells. Immobilized or soluble H57-597 antibody can activate a/? TCR-bearing T cells. Additional reported applications (for the relevant formats) for this antibody include: immunoprecipitation2, in vitro stimulation2,3, in vivo depletion4-6, and immunohistochemical staining of acetone-fixed frozen sections7,8,9. The Ultra-LEAF? purified antibody (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 109253-109258).

Application References

(PubMed link indicates BioLegend citation)
  1. Gascoigne NJ. 1990. J. Biol. Chem. 265:9296.
  2. Kruisbeek A, et al. 1991. In Current Protocols in Immunology. pp. 3.12.1. (Costim IP)
  3. Davenport C, et al. 1995. J. Immunol. 155:3742. (Costim)
  4. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  5. Kummer U, et al. 2001. Immunol. Lett. 75:153. (Deplete)
  6. van der Heyde HC, et al. 1995. J. Immunol. 154:3985. (Deplete)
  7. Tomita K, et al. 1999. Genes Dev. 13:1203. (IHC)
  8. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  9. Ponomarev ED, et al. 2007. J. Immunol. 178:39. (IHC)
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Tsukumo S, et al. 2006. J.Immunol. 177:8365. (FC) PubMed
  12. Grégoire C, et al. 1991. Proc. Natl. Acad. Sci USA 88:8077.
Product Citations
  1. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  2. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  3. Lee SA, et al. 2020. J Immunol. 204:586. PubMed
  4. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  5. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  6. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  7. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
  8. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  9. Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed
  10. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  11. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  12. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  13. Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  14. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  15. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  16. Prosser A, et al. 2021. Cell Reports. 35(7):109141. PubMed
  17. Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed
  18. Romano A, et al. 2015. J Immunol. 195: 3816 - 3827. PubMed
  19. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
  20. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  21. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  22. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  23. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  24. Lu X, et al. 2020. Sci Transl Med. 12:. PubMed
  25. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  26. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  27. Goh PK, et al. 2022. Sci Adv. 8:eabk3338. PubMed
  28. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  29. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  30. Xiao S, et al. 2020. Cell Reports. 32(2):107892. PubMed
  31. Peters N, et al. 2014. PLoS Pathog. 10:1004538. PubMed
  32. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  33. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  34. Wei Y, et al. 2021. Endocrinology. 162(8):. PubMed
  35. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  36. Baja?a S, et al. 2022. iScience. 25:103732. PubMed
  37. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  38. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  39. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
  40. Ito Y, et al. 2021. Cell Reports. 35(4):109052. PubMed
  41. Trivedi S, et al. 2020. Elife. 9:00. PubMed
RRID
AB_10933263 (BioLegend Cat. No. 109229) AB_2562562 (BioLegend Cat. No. 109230)

Antigen Details

Structure
Ig superfamily, CD3/TCR complex with CD3 and TCR α subunit
Distribution

Majority of T cells and thymocytes (correlated to differentiation)

Function
Antigen recognition, T cell activation
Ligand/Receptor
Peptide bound-MHC class I and II
Antigen References

1. Davis MM, et al. 1998. Ann. Rev. Immunol. 16:523.
2. Huppa JB, et al. 2003. Nat. Immunol. 4:749.
3. Kubo R, et al. 1989. J. Immunol. 142:2736.

Gene ID
21577 View all products for this Gene ID
UniProt
View information about TCR beta chain on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线